Swarthmore Group Inc adds Thermo Fisher Scientific (TMO) to its portfolio

Thermo Fisher Scientific (TMO) : Swarthmore Group Inc added new position in Thermo Fisher Scientific during the most recent quarter end. The investment management firm now holds 166,800 shares of Thermo Fisher Scientific which is valued at $24,242,712 , the company said in a statement filed on Apr 13, 2016 with the SEC.Thermo Fisher Scientific makes up approximately 3.66% of Swarthmore Group Inc’s portfolio.

Thermo Fisher Scientific opened for trading at $145.42 and hit $146.6 on the upside on Monday, eventually ending the session at $146.47, with a gain of 0.78% or 1.13 points. The heightened volatility saw the trading volume jump to 9,07,628 shares. Company has a market cap of $58,040 M.

Other Hedge Funds, Including , Churchill Management Corp added TMO to its portfolio by purchasing 9,278 company shares during the most recent quarter which is valued at $1,348,465. Thermo Fisher Scientific makes up approx 0.09% of Churchill Management Corp’s portfolio.Consulta Ltd reduced its stake in TMO by selling 75,000 shares or 30.0% in the most recent quarter. The Hedge Fund company now holds 175,000 shares of TMO which is valued at $25,434,500. Thermo Fisher Scientific makes up approx 3.08% of Consulta Ltd’s portfolio.Dnb Asset Management As boosted its stake in TMO in the latest quarter, The investment management firm added 16,900 additional shares and now holds a total of 70,993 shares of Thermo Fisher Scientific which is valued at $10,318,123. Thermo Fisher Scientific makes up approx 0.21% of Dnb Asset Management As’s portfolio.Graybill Bartz Assoc Ltd boosted its stake in TMO in the latest quarter, The investment management firm added 130 additional shares and now holds a total of 26,970 shares of Thermo Fisher Scientific which is valued at $3,820,570. Thermo Fisher Scientific makes up approx 3.50% of Graybill Bartz Assoc Ltd’s portfolio.

On the company’s financial health, Thermo Fisher Scientific reported $2.12 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $2.11. The company had revenue of $4652.50 million for the quarter, compared to analysts expectations of $4551.79 million. The company’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.99 EPS.

Many Wall Street Analysts have commented on Thermo Fisher Scientific. Company shares were Reiterated by Mizuho on Apr 4, 2016 to “Buy”, Firm has raised the Price Target to $ 160 from a previous price target of $150 .Company shares were Reiterated by Topeka Capital Markets on Mar 2, 2016 to “Buy”, Firm has raised the Price Target to $ 155 from a previous price target of $145 .

Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.

Leave a Reply

Thermo Fisher Scientific - Is it time to Sell?

Top Brokerage Firms are advising their investors on Thermo Fisher Scientific. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.